RxDoctor Payments Data

Eric Ellis, MD

Emergency Medicine · Lincoln, CANPI 1215968409

Payments from drug & device makers

$655in general payments, 2019–2025

Across 14 payments — averaging $46.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mckesson Medical-surgical, Inc.$287
  • Galderma Laboratories, L.p.$88
  • Abbott$53
  • Talis Biomedical Corporation$53
  • Quidel Corporation$33
  • AbbVie$29
  • plus $112 from 6 others

What the payments were for

  • Consulting fees$203%
  • Food & beverage$63597%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Mckesson Medical-surgical, Inc.1$287
Galderma Laboratories, L.p.1$88
Abbott3$53
Talis Biomedical Corporation1$53
Quidel Corporation1$33
AbbVie1$29
Pfizer1$21
PTC Therapeutics, Inc.1$20
Hologic Sales And Service, LLC1$20
AstraZeneca1$19
Genentech USA, Inc.1$19
Lilly USA, LLC1$14

How this compares

$655 in reported general payments places this provider in the 90th percentile of 6,006 emergency medicine providers in California.

See all emergency medicine providers in California

Medicare billing

Part B allowed, 2024
$365,447
Medicare patients
1,709
Services billed
8,030

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin12$7,450
Albuterol Sulfate HfaAlbuterol Sulfate44$726
Tamsulosin Hcl24$460
Losartan Potassium22$437
Cephalexin65$404
Atorvastatin Calcium40$392
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip14$387
Levothyroxine Sodium22$377
Doxycycline Hyclate39$323
Omeprazole14$299
Lisinopril30$278
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav28$245
Amlodipine Besylate17$240
Prednisone67$236
Methylprednisolone32$203

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPaxlovid$21$019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,006 emergency medicine providers in California.

Other emergency medicine in Lincoln

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →